(4R)-4-[(furan-2-yl)hydroxymethyl]-1-(triisopropylsilanyl)azetidin-2-one | 250135-54-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4R)-4-[(furan-2-yl)hydroxymethyl]-1-(triisopropylsilanyl)azetidin-2-one
• CAS: 250135-54-7
• 化学式: C₁₇H₂₉NO₃Si
• 分子量: 323.508
• InChiKey: COMXORWVHDFFEW-XPCCGILXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.09
• 重原子数：
  22.0
• 可旋转键数：
  6.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  53.68
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (4R)-4-[(furan-2-yl)hydroxymethyl]-1-(triisopropylsilanyl)azetidin-2-one 在 4-二甲氨基吡啶 、 偶氮二异丁腈 、 三苯基氢化锡 、 cesium fluoride 作用下， 以 甲醇 、 二氯甲烷 、 苯 为溶剂， 反应 1.0h， 生成 (4S)-4-[(furan-2-yl)methyl]azetidin-2-one
  参考文献：
  名称：

  Synthesis and antiviral activity of monobactams inhibiting the human cytomegalovirus protease

  摘要：

  A series of monobactam inhibitors of HCMV (N-o) protease bearing a heterocycle linked by a methylene group at C-4 is described. Inhibitors containing a heterocycle such as a 2-furyl, 2-thiophenyl, 4-methyl-2-tetrazole and 2-benzothiazole were found to be active in a plaque reduction assay. Furthermore, 2-benzothiazole derivatives were shown to inhibit the HCMV protease activity inside cells by using a cell transfection assay, indicating that their antiviral activity in the plaque reduction assay could be attributed to protease inhibition. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00094-2
• 作为产物：
  描述：

  (4R)-4-hydroxymethyl-1-(triisopropylsilanyl)azetidin-2-one 在 正丁基锂 、 戴斯-马丁氧化剂 作用下， 以 乙醚 、 正己烷 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 (4R)-4-[(furan-2-yl)hydroxymethyl]-1-(triisopropylsilanyl)azetidin-2-one
  参考文献：
  名称：

  Synthesis and antiviral activity of monobactams inhibiting the human cytomegalovirus protease

  摘要：

  A series of monobactam inhibitors of HCMV (N-o) protease bearing a heterocycle linked by a methylene group at C-4 is described. Inhibitors containing a heterocycle such as a 2-furyl, 2-thiophenyl, 4-methyl-2-tetrazole and 2-benzothiazole were found to be active in a plaque reduction assay. Furthermore, 2-benzothiazole derivatives were shown to inhibit the HCMV protease activity inside cells by using a cell transfection assay, indicating that their antiviral activity in the plaque reduction assay could be attributed to protease inhibition. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00094-2